Influence of antibiotics of different groups on the course of community-acquired pneumonia in children
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2023.1.13384Keywords:
community-acquired pneumonia, antibiotics, inpatient treatmentAbstract
Summary. The article provides the results of the use of protected aminopenicillins and cephalosporins in the treatment of community-acquired pneumonia in children in hospital conditions. Their comparative influence on the course of pneumonia, the dynamics of symptoms, data of additional research methods is demonstrated. It has been proven that protected penicillins are much more effective than cephalosporins.
The aim of the study – to providie physicians with up-to-date information on choice of antibiotics for the treatment of community-acquired pneumonia in children.
Materials and Methods. The study involved 40 children, aged 3 months – 5 years old with community-acquired pneumonia. 20 children received protected aminopenicillins, 20 children received cephalosporins. The dynamics of the course of pneumonia was studied. The indicators of the number of leccocytes, neutrophils, and the rate of erythrocyte sedimentation were taken into account. The state of the radiograph of the lungs was taken into account.
Results. In examined children. who received protected aminopenicillins, complaints of cough, general weakness, headache regressed on the 7–8th day of treatment, while in patients who received cephalosporins, complaints occurred until the 10th day of treatment. Auscultatory and radiographic changes, as well as a decrease in the inflammatory syndrome in laboratory examinations by an average of 30 %, were more dynamic under the influence of treatment in patients who received protected aminopenicillins.
Conclusions. Adherence to the recommendations of the WHO (2017) on antibacterial therapy contributes to the greater effectiveness of the dynamics of symptoms. During treatment, preference should be given to antibiotics of the ACCESS group (availability), which includes amoxicillin and amoxicillin/clavulanate, over drugs of the WATCH group (observation), which include, among others, cephalosporins of the 3rd generation, which are drugs of choice and reserve, since their use increases the risk of developing resistance.
References
Mokiya-Serbina SA, Litvinova TV, Zabolotnyaya NI, Tsyktor SV. Starting empirical antibiotic therapy in treatment of severe community - acquired pneumonia in children under 5 years. Modern Methodology of Science and Education. 2017;4; 22-5.
Maydannyk VH, Yemchynska YeO. Clinical guidelines for diagnosis and treatment of community-acquired pneumonia in children from the standpoint of evidence-based medicine. [Клінічні настанови з діагностики та лікування позалікарняної пневмонії у дітей з позиції доказової медицини] Kyiv; 2014 Ukrainian.
Rudan I. Epidemiology and etiology of childhood pneumonia. Bulletin of the World Health Organization. 2008;86(5): 408-16.
Everard ML., Graven V, Fenton P. Community-acquired pneumonia. ERS handbook Paediatric Respiratory Medicie. Ist Ed. Eds. E.Eber, F.Medulla. Published by the European Respiratory Society. 2013;233-41.
Torumkuney D, Nica M, Nistor I, Vatcheva-Dobrevska R, Petrovic V, Stoica A et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-2016 in Bulgaria, Romania, Serbia and Croatia. Journal of Antimicrobial Chemotherapy. 2018;73(5):2-13.
Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, Thomson A. British Thoracic Society clinical protocol for the management of community-acquired pneumonia in children: 2011 update. Such pediatr. 2017; 8(88): 130-59. Ukrainian.
Yakovlev SV, Rafalskyy VV, Sydorenko SV, Spychak TV. Strategy and tactics of rational use of antimicrobial agents in outpatient practice: Eurasian clinical guidelines. Evraz klin rek. 2016;144. Russian
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Bulletin of Medical and Biological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
